最新公布的Rezolve-AD临床试验维持期研究数据显示，免疫调节剂Rezpegaldesleukin在特应性皮炎治疗中展现出突破性疗效。无论是每月给药还是每季度给药方案，该药物均在瘙痒程度、皮损面积、生活质量等核心评估指标上引发持续性缓解，并激发新的治疗应答。
值得注意的是，这种双重给药频率的灵活性为个体化治疗提供了更多选择。长期随访证实，患者在接受治疗后不仅原有症状得到控制，更在多个关键临床终点出现新增改善迹象。这一发现标志着慢性皮肤病治疗领域的重要进展，为复发率高的特应性皮炎患者提供了可持续控制病情的潜在方案。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.